When many cancers advance, spread and reoccur, checkpoint inhibitors can help keep difficult tumors at bay. These antibody-based immunotherapies can restore the body’s ability to recognize and ...

Checkpoint inhibitors are antibody-based cancer therapies that unlock the immune system’s natural ability to fight cancer. These treatments work by blocking special proteins called immune checkpoints, ...

Natural killer (NK) cells are pivotal in the innate immune response against cancer and viral infections, with their presence in tumors correlating to better patient outcomes in various cancers.

A research team led by Professor Ki-Young Lee at the College of Medicine, Sungkyunkwan University, has uncovered a previously unrecognized tumor-intrinsic role of the immune checkpoint molecule PD-L1, ...

PD-L1 and alternative immune checkpoints (AICs) in non-small cell lung cancer (NSCLC): Insights into the tumor immune microenvironment (TIME) and immunotherapy (IO) outcomes. This is an ASCO Meeting ...

Checkpoint Therapeutics, Inc. announced that the FDA has approved UNLOXCYT™ (cosibelimab-ipdl) for treating adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who ...

Impact of initial local therapy (LT) in the combination treatment era for metastatic renal cell carcinoma (mRCC): Subgroup analysis from ProPaxi study. Mortality risk in clinical T1a renal cell ...